Team

Newton Biocapital is managed by life sciences entrepreneurs Alain Parthoens and Goro Takeda. Together with a team of experienced industry and venture capital professionals, they leverage their strategic insights to create value for both patients and investors.

Operational

Alain Parthoens

Alain
Parthoens

ir / Managing Partner

  • 20 years in the food and biotech industries (Nestle, Monsanto/Searle, PWC)
  • 15 years of venture capital (ING Bank, Vesalius Biocapital)
  • 30 investments in early and neglected late-stage companies, typically as lead investor
  • Director of Ogeda, Promethera Biosciences, Profibrix, Voluntis, NCardia (ex-Pluriomics) and Epics Therapeutics
  • Formerly Chairman of the BVA and member of the Invest Europe VC council
  • Based in Brussels
Goro

Goro
Takeda

MBA / Managing Partner

  • 9 years in the pharmaceutical industry in the US
  • 15 years of venture capital (NIF SMBC Ventures, Sofinnova Ventures, and co-founder of FinTech Global Capital - FGF)
  • Over 20 investments in small biotechs, multiple IPOs and trade sales
  • Based in Tokyo
Els

Els
Hubloux

ir / MBA
Investment Partner

  • 19 years in clinical R&D, financial analysis, and management
  • 14 years in venture capital (KBCPE, Capricorn Venture Partners, QBIC Venture Partners)
  • Over 20 transactions in small biotechs, several IPOs and trade sales
  • Based in Brussels
Guy Heynen

Guy
Heynen

MD
Senior Clinical &
Regulatory Partner

  • Chief Clinical and Regulatory Officer of Bone Therapeutics (regenerative medicine)
  • Joined Pfizer in 1982; served as Medical Director for Pfizer Switzerland and as International Medical Director up to 2000, and as Regional Medical monitor for Pfizer up to 2014.
  • Independent Director of Ogeda and Pluriomics
Pierre

Pierre
Detrixhe

ir / Master in Management
Investment Partner

  • Background in bio-engineering with previous experience as a scientist in biotech and a technology transfer officer
  • More than 10 years in venture capital (Investsud Group)
  • 10 investments in early stage companies
  • Director at ATB Therapeutics, Bioxodes, Synergia Medical
  • Based in Brussels
Louis

Louis
de Thanhoffer
de Völcsey

Senior Pharma
Biotech Advisor

  • Started his career as a research scientist at the Pasteur Institute and in Pr. Dr. Walter Fiers' Lab of Molecular Biology at the State University of Ghent (Belgium)
  • Joined Janssen Pharmaceutica in 1983 at the request of Dr. Paul Janssen to create the Lab of Molecular Genetics in the Janssen Life Sciences Department
  • In 2000, set up a healthcare/biotech team at Petercam, a Brussels-based stockbrokerage firm (noz Degroof Petercam Bank)
  • From 2008 until 2013, he joined Hunza Ventures, a life sciences private equity fund that belongs to a family office
Dario Padovani

Dario
Padovani

BS CS / EMM
Administration & Finances

  • 20 years in the chemical industry (Monsanto, Searle)
  • 11 years in insurance industry, 8 years in the distribution & logistics industries
  • Based in Brussels
Danny Gonnissen

Danny
Gonnissen

PhD Appl. Sc. / Head of Administration and Finance

  • 13 years in industry
  • 8 years of venture capital (Bekaert Venturing, Qbic Fund) with expertise in Direct Investments and Fund Investments
  • Board seats in start-ups & scale-ups
  • Based in Brussels

Board-of-directors

Ajit

Ajit
Shetty

Chairman
(Independent director)

  • Formerly CEO, Chairman of Janssen Pharmaceutica
  • Vice President Enterprise Supply Chain for Johnson & Johnson
Dirk

Dirk
Boogmans

Vice-Chairman
Independent director

  • CEO of construction group CFE (1998 - 2001), CEO of GIMV (2001-2008)
  • Board of Director member at BNP Paribas Fortis (Since 2009)
Jean Claude Deschamps

Jean-Claude
Deschamps

Chairman Emeritus

  • Substantial industrial and venture capital experience
  • Instrumental in funding several worldwide recognized projects, including IMEC